( OTC-BB:SRNE, OTC-PINK:SRNE )

News from Sorrento Therapeutics, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

15 May, 2015, 10:38 ET NantWorks verwerft Cynviloq™ voor minimaal $ 1,3 miljard

--Betaling van minimaal $ 90 miljoen vooraf en minimaal $ 1,2 miljard aan mijlpaalbetalingen --Sorrento behoudt optie voor de gezamenlijke...


04 May, 2015, 10:44 ET Sorrento gibt positive Ergebnisse für TRIBECA™ Zulassungsstudie bekannt

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) freut sich, positive Ergebnisse der vor kurzem analysierten pharmakokinetischen (PK) Daten aus seiner...


04 May, 2015, 09:31 ET Sorrento kondigt een positief resultaat aan van het TRIBECA™-registratieonderzoek

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is verheugd met de bekendmaking van het positieve resultaat van de onlangs geanalyseerde...


04 May, 2015, 09:00 ET Sorrento Announces Positive TRIBECA™ Registrational Study Results

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is pleased to announce positive results from recently analyzed pharmacokinetic (PK) data from its...


17 Mar, 2015, 07:20 ET NantWorks et Sorrento annoncent une deuxième collaboration mondiale complète sur la découverte et le développement de nouvelles immunothérapies anticancéreuses

- NantCell acquiert les droits exclusifs d'anticorps comprenant les produits CAR-TNK™ et les inhibiteurs des points de contrôle PD-1 et...


17 Mar, 2015, 07:14 ET NantWorks en Sorrento kondigen tweede brede wereldwijde samenwerking aan in de ontdekking en ontwikkeling van nieuwe immunotherapieën tegen kanker

- NantCell zal exclusieve rechten verwerven op antilichamen waaronder CAR-TNK™ Producten en de checkpointremmers PD-1 en PD-L1  NantWorks,...


16 Mar, 2015, 13:56 ET NantWorks und Sorrento kündigen ihre zweite, umfassende, weltweite Kooperation bei der Entdeckung und Entwicklung neuartiger Immunotherapien gegen Krebs an

- NantCell erwirbt die exklusiven Rechte an Antikörpern, wie den CAR-TNK™ Produkten und den Checkpoint-Inhibitoren PD-1 und PD-L1  NantWorks,...


16 Mar, 2015, 09:00 ET NantWorks And Sorrento Announce Second Comprehensive Global Collaboration On Discovery And Development Of Novel Anti-Cancer Immunotherapies

 NantWorks, Inc. and Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), announced today that they have entered into a...


05 Feb, 2015, 09:00 ET Sorrento to Present at the 17th Annual BIO CEO & Investor Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated...


02 Feb, 2015, 09:00 ET Sorrento Announces Retention of Glen Sato to Provide Strategic Support

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced...


28 Jan, 2015, 14:41 ET Sorrento kondigt afronding aan van deelname aan het Cynviloq™ TRIBECA™ registratieonderzoek

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), een oncologiebedrijf dat nieuwe behandelingen voor kanker en aanverwante pijn ontwikkelt,...


28 Jan, 2015, 12:00 ET Sorrento annonce la fin du recrutement dans l'étude TRIBECA™ d'enregistrement Cynviloq™

Sorrento Therapeutics, Inc. (NASDAQ : SRNE ; Sorrento), la société d'oncologie qui développent de nouveaux traitements contre le cancer et les...


28 Jan, 2015, 09:00 ET Sorrento Announces Completion of Enrollment in the Cynviloq™ Registrational TRIBECA™ Study

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today...


28 Jan, 2015, 09:00 ET Sorrento gibt Ende der Rekrutierung für die Cynviloq™ TRIBECA™-Zulassungsstudie bekannt

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), ein Onkologieunternehmen, das neue Behandlungsmethoden für Krebs und damit verbundene...


12 Jan, 2015, 09:00 ET Sorrento Provides Status Update on the Cynviloq™ Registrational TRIBECA™ Study

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced...


06 Jan, 2015, 09:00 ET Conkwest, Sorrento And NantWorks Announce Presentation At The 33rd Annual J. P. Morgan Healthcare Conference By Dr. Patrick Soon-Shiong

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and Conkwest, Inc., an...


05 Jan, 2015, 09:00 ET Sorrento To Present At The 2015 Biotech Showcase And 8th Annual OneMedForum In San Francisco

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and...


19 Dec, 2014, 06:00 ET Sorrento and Conkwest Announce Exclusive Global Collaboration

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE;  Sorrento), an oncology company developing new treatments for cancer and associated pain, and...


15 Dec, 2014, 09:25 ET Sorrento Announces Strategic Investment By And Collaboration With Nantworks Founder Dr. Patrick Soon-Shiong For The Advancement Of Cancer Immunotherapies

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today...


08 Dec, 2014, 09:15 ET Sorrento Therapeutics Announces Poster Presentations on its Anti-c-Met/PD-L1 Bispecific Antibodies and Anti-c-Met-Antibody Drug Conjugate at the 37th Annual San Antonio Breast Cancer Symposium

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated...